{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:45:02Z","timestamp":1790891102079,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,19]]},"DOI":"10.7759\/cureus.62698","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T13:32:01Z","timestamp":1718803921000},"source":"Crossref","is-referenced-by-count":5,"title":["Treatment and Toxicity Considerations in Tuberculosis: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Nicholas  T","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raegan","family":"Abadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camryn  L","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamryn","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd  F","family":"Ledet III","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia  E","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent  G","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Potharaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Siddaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7012a4","article-title":"Epidemiology of tuberculosis and progress toward meeting global targets - worldwide, 2019","volume":"70","author":"Fukunaga R","year":"2021","unstructured":"Fukunaga R, Glaziou P, Harris JB, Date A, Floyd K, Kasaeva T. Epidemiology of tuberculosis and progress toward meeting global targets - worldwide, 2019. MMWR Morb Mortal Wkly Rep. 2021, 70:427-30. 10.15585\/mmwr.mm7012a4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00299-0","article-title":"Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis","volume":"9","author":"Silva S","year":"2021","unstructured":"Silva S, Arinaminpathy N, Atun R, Goosby E, Reid M. Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis. Lancet Glob Health. 2021, 9:E1372-9. 10.1016\/S2214-109X(21)00299-0","journal-title":"Lancet Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202011-4239PP","article-title":"Latent tuberculosis: two centuries of confusion","volume":"204","author":"Behr MA","year":"2021","unstructured":"Behr MA, Kaufmann E, Duffin J, Edelstein PH, Ramakrishnan L. Latent tuberculosis: two centuries of confusion. Am J Respir Crit Care Med. 2021, 204:142-8. 10.1164\/rccm.202011-4239PP","journal-title":"Am J Respir Crit Care Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0185","article-title":"Mechanisms of mycobacterial transmission: how does Mycobacterium tuberculosis enter and escape from the human host","volume":"11","author":"Shiloh MU","year":"2016","unstructured":"Shiloh MU. Mechanisms of mycobacterial transmission: how does Mycobacterium tuberculosis enter and escape from the human host. Future Microbiol. 2016, 11:1503-6. 10.2217\/fmb-2016-0185","journal-title":"Future Microbiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02302-2018","article-title":"Detection, survival and infectious potential of Mycobacterium tuberculosis in\u00a0the environment: a review of the evidence and epidemiological implications","volume":"15","author":"Martinez L","year":"2019","unstructured":"Martinez L, Verma R, Croda J, et al.. Detection, survival and infectious potential of Mycobacterium tuberculosis in\u00a0the environment: a review of the evidence and epidemiological implications. Eur Respir J. 2019, 15:53. 10.1183\/13993003.02302-2018","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9050385","article-title":"Mycobacterium tuberculosis pathogenesis, infection prevention and treatment","volume":"9","author":"Miggiano R","year":"2020","unstructured":"Miggiano R, Rizzi M, Ferraris DM. Mycobacterium tuberculosis pathogenesis, infection prevention and treatment. Pathogens. 2020, 9:385. 10.3390\/pathogens9050385","journal-title":"Pathogens"},{"key":"ref7","unstructured":"Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. (2023). Accessed. June 20, 2023: https:\/\/pubmed.ncbi.nlm.nih.gov\/21234341\/."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-020-11062-4","article-title":"Skin tests for the detection of Mycobacterial infections: achievements, current perspectives, and implications for other diseases","volume":"105","author":"Duthie MS","year":"2021","unstructured":"Duthie MS, Reed SG. Skin tests for the detection of Mycobacterial infections: achievements, current perspectives, and implications for other diseases. Appl Microbiol Biotechnol. 2021, 105:503-8. 10.1007\/s00253-020-11062-4","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00272-20","article-title":"Accuracy of QuantiFERON-TB Gold Plus Test for diagnosis of Mycobacterium tuberculosis infection in children","volume":"58","author":"Buonsenso D","year":"2020","unstructured":"Buonsenso D, Delogu G, Perricone C, et al.. Accuracy of QuantiFERON-TB Gold Plus Test for diagnosis of Mycobacterium tuberculosis infection in children. J Clin Microbiol. 2020, 58:10.1128\/JCM.00272-20","journal-title":"J Clin Microbiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00096-21","article-title":"Retrospective performance analyses of over two Million U.S. QuantiFERON blood sample results","volume":"9","author":"Bi C","year":"2021","unstructured":"Bi C, Clark RB, Master R, Kapoor H, Kroll MH, Salm AE, Meyer WA 3rd. Retrospective performance analyses of over two Million U.S. QuantiFERON blood sample results. Microbiol Spectr. 2021, 9:e0009621. 10.1128\/Spectrum.00096-21","journal-title":"Microbiol Spectr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.16-0579","article-title":"First Insight into the fluoroquinolone and aminoglycoside resistance of multidrug-resistant mycobacterium tuberculosis in Saudi Arabia","volume":"96","author":"Varghese B","year":"2017","unstructured":"Varghese B, Al-Hajoj S. First Insight into the fluoroquinolone and aminoglycoside resistance of multidrug-resistant mycobacterium tuberculosis in Saudi Arabia. Am J Trop Med Hyg. 2017, 96:1066-70. 10.4269\/ajtmh.16-0579","journal-title":"Am J Trop Med Hyg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2021.08.034","article-title":"Changing paradigms in the treatment of tuberculosis","volume":"69","author":"Chawla R","year":"2022","unstructured":"Chawla R, Rani V, Mishra M. Changing paradigms in the treatment of tuberculosis. Indian J Tuberc. 2022, 69:389-403. 10.1016\/j.ijtb.2021.08.034","journal-title":"Indian J Tuberc"},{"key":"ref13","unstructured":"Patient adherence to tuberculosis treatment. a systematic review of qualitative research. (2023). Accessed: June 20, 2023: https:\/\/journals.plos.org\/plosmedicine\/article?id=10.1371\/journal.pmed.0040238."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2019.04.012","article-title":"Pharmacokinetics of isoniazid: the good, the bad, and the alternatives","volume":"116S","author":"Erwin ER","year":"2019","unstructured":"Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC. Pharmacokinetics of isoniazid: the good, the bad, and the alternatives. Tuberculosis (Edinb). 2019, 116S:S66-70. 10.1016\/j.tube.2019.04.012","journal-title":"Tuberculosis (Edinb)"},{"key":"ref15","article-title":"Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol","volume":"12","author":"Dave A","year":"2022","unstructured":"Dave A, Shah S, Mistry Y, Chaturvedi N, Jariwala D. Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol.  Natl J Physiol Pharm Pharmacol. 2022, 12:127-31.","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.24911\/SJP.106-1584524803","article-title":"Pyridoxine in isoniazid-induced psychosis","volume":"22","author":"Yadav R","year":"2022","unstructured":"Yadav R, Kumar M, Kumar N, Chacham S. Pyridoxine in isoniazid-induced psychosis. Sudan J Paediatr. 2022, 22:190-2. 10.24911\/SJP.106-1584524803","journal-title":"Sudan J Paediatr"},{"key":"ref17","article-title":"Effects of rifampicin plus levofloxacin or isoniazid on immune function of patients with pulmonary tuberculosis","volume":"AT10135","author":"Lv F","year":"2024","unstructured":"Lv F, Tang N. Effects of rifampicin plus levofloxacin or isoniazid on immune function of patients with pulmonary tuberculosis. Altern Ther Health Med. 2024, AT10135:135.","journal-title":"Altern Ther Health Med"},{"key":"ref18","article-title":"Rifampin","volume":"106","author":"Schonell M","year":"1972","unstructured":"Schonell M, Dorken E, Grzybowski S. Rifampin. Can Med Assoc J. 1972, 106:783-6.","journal-title":"Can Med Assoc J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.9.985","article-title":"Rifampin and rifabutin drug interactions: an update","volume":"162","author":"Finch CK","year":"2002","unstructured":"Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002, 162:985-92. 10.1001\/archinte.162.9.985","journal-title":"Arch Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528020-00003","article-title":"Clinical pharmacokinetics of rifabutin","volume":"28","author":"Skinner MH","year":"1995","unstructured":"Skinner MH, Blaschke TF. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet. 1995, 28:115-25. 10.2165\/00003088-199528020-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref21","article-title":"Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review","volume":"13","author":"Gao XF","year":"2009","unstructured":"Gao XF, Li J, Yang ZW, Li YP. Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2009, 13:810-9.","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ766","article-title":"Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York city health department clinics","volume":"62","author":"Stennis NL","year":"2016","unstructured":"Stennis NL, Burzynski JN, Herbert C, Nilsen D, Macaraig M. Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York city health department clinics. Clin Infect Dis. 2016, 62:53-9. 10.1093\/cid\/civ766","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31814a586a","article-title":"Update on rifampin and rifabutin drug interactions","volume":"335","author":"Baciewicz AM","year":"2008","unstructured":"Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008, 335:126-36. 10.1097\/MAJ.0b013e31814a586a","journal-title":"Am J Med Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa460","article-title":"Pharmacology, dosing, and side effects of rifabutin as a possible therapy for antibiotic-resistant acinetobacter infections","volume":"7","author":"Phillips MC","year":"2020","unstructured":"Phillips MC, Wald-Dickler N, Loomis K, Luna BM, Spellberg B. Pharmacology, dosing, and side effects of rifabutin as a possible therapy for antibiotic-resistant acinetobacter infections. Open Forum Infect Dis. 2020, 7:ofaa460. 10.1093\/ofid\/ofaa460","journal-title":"Open Forum Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.16783.1","article-title":"Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]","volume":"6","author":"Davis AG","year":"2021","unstructured":"Davis AG, Wasserman S, Maxebengula M, et al.. Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]. Wellcome Open Res. 2021, 6:136. 10.12688\/wellcomeopenres.16783.1","journal-title":"Wellcome Open Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.05.002","article-title":"High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin","volume":"133","author":"Souleymane MB","year":"2023","unstructured":"Souleymane MB, Kadri S, Piubello A, et al.. High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin. Int J Infect Dis. 2023, 133:78-81. 10.1016\/j.ijid.2023.05.002","journal-title":"Int J Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad051","article-title":"Comparing efficacy and safety of high-dose and standard-dose rifampicin in the treatment of brucellosis: a randomized clinical trial","volume":"78","author":"Salehi M","year":"2023","unstructured":"Salehi M, Farbod F, Khalili H, Rahmani H, Jafari S, Abbasi A. Comparing efficacy and safety of high-dose and standard-dose rifampicin in the treatment of brucellosis: a randomized clinical trial. J Antimicrob Chemother. 2023, 78:1084-91. 10.1093\/jac\/dkad051","journal-title":"J Antimicrob Chemother"},{"key":"ref28","unstructured":"Pyrazinamide. In. LiverTox: Clinical and research information on drug-induced liver injury. (2012). Accessed: June 28, 2023: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547856\/."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MGM2-0023-2013","article-title":"Mechanisms of pyrazinamide action and resistance","volume":"2","author":"Zhang Y","year":"2013","unstructured":"Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr. 2013, 2:1-12. 10.1128\/microbiolspec.MGM2-0023-2013","journal-title":"Microbiol Spectr"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106914","article-title":"Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review","volume":"62","author":"Chen RH","year":"2023","unstructured":"Chen RH, Michael T, Kuhlin J, Sch\u00f6n T, Stocker S, Alffenaar JC. Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review. Int J Antimicrob Agents. 2023, 62:106914. 10.1016\/j.ijantimicag.2023.106914","journal-title":"Int J Antimicrob Agents"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00003-22","article-title":"Population pharmacokinetic modelling and limited sampling strategies for therapeutic drug monitoring of pyrazinamide in patients with tuberculosis","volume":"66","author":"Abolhassani-Chimeh R","year":"2022","unstructured":"Abolhassani-Chimeh R, Akkerman OW, Saktiawati AM, et al.. Population pharmacokinetic modelling and limited sampling strategies for therapeutic drug monitoring of pyrazinamide in patients with tuberculosis. Antimicrob Agents Chemother. 2022, 66:e0000322. 10.1128\/aac.00003-22","journal-title":"Antimicrob Agents Chemother"},{"key":"ref32","unstructured":"(Pyrazinamide) dosing, indications, interactions, adverse effects, and more. (2023). Accessed. June 28, 2023: https:\/\/reference.medscape.com\/drug\/pyrazinamide-342678."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133869","article-title":"A global perspective on pyrazinamide resistance: systematic review and meta-analysis","volume":"10","author":"Whitfield MG","year":"2015","unstructured":"Whitfield MG, Soeters HM, Warren RM, et al.. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. PLoS One. 2015, 10:e0133869. 10.1371\/journal.pone.0133869","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.121.000389","article-title":"Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug","volume":"49","author":"Hussain Z","year":"2021","unstructured":"Hussain Z, Zhu J, Ma X. Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug. Drug Metab Dispos. 2021, 49:679-82.","journal-title":"Drug Metab Dispos"},{"key":"ref35","article-title":"Pyrazinamide-induced hyperuricemia","volume":"39","author":"Pham AQ","year":"2014","unstructured":"Pham AQ, Doan A, Andersen M. Pyrazinamide-induced hyperuricemia. P T. 2014, 39:695-715.","journal-title":"P T"},{"key":"ref36","article-title":"Ethambutol","author":"Lee N","year":"2024","unstructured":"Lee N, Patel P, Nguyen H. Ethambutol. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2023.03.009","article-title":"Ethambutol and its ophthalmic effects; is screening and collaboration the new way forward?","volume":"71","author":"Vyas A","year":"2024","unstructured":"Vyas A, Subramanyam A, Phatak S, Tiwari S. Ethambutol and its ophthalmic effects; is screening and collaboration the new way forward?. Indian J Tuberc. 2024, 71:30-4. 10.1016\/j.ijtb.2023.03.009","journal-title":"Indian J Tuberc"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054788","article-title":"Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)","volume":"12","author":"Ekqvist D","year":"2022","unstructured":"Ekqvist D, Bornefall A, Augustinsson D, et al.. Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). BMJ Open. 2022, 12:e054788. 10.1136\/bmjopen-2021-054788","journal-title":"BMJ Open"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials","volume":"20","author":"Campbell JR","year":"2020","unstructured":"Campbell JR, Trajman A, Cook VJ, et al.. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2020, 20:318-29. 10.1016\/S1473-3099(19)30575-4","journal-title":"Lancet Infect Dis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.13824","article-title":"Level of adherence to anti-tubercular treatment among drug-sensitive tuberculosis patients on a newly introduced daily dose regimen in South India: a cross-sectional study","volume":"27","author":"Thamineni R","year":"2022","unstructured":"Thamineni R, Peraman R, Chenniah J, Meka G, Munagala AK, Mahalingam VT, Ganesan RM. Level of adherence to anti-tubercular treatment among drug-sensitive tuberculosis patients on a newly introduced daily dose regimen in South India: a cross-sectional study. Trop Med Int Health. 2022, 27:1013-23. 10.1111\/tmi.13824","journal-title":"Trop Med Int Health"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00359-7","article-title":"WHO's global tuberculosis report 2022","volume":"4","author":"Bagcchi S","year":"2023","unstructured":"Bagcchi S. WHO's global tuberculosis report 2022. Lancet Microbe. 2023, 4:20. 10.1016\/S2666-5247(22)00359-7","journal-title":"Lancet Microbe"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.22.0263","article-title":"WHO drug-resistant TB guidelines 2022: what is new?","volume":"26","author":"Migliori GB","year":"2022","unstructured":"Migliori GB, Tiberi S. WHO drug-resistant TB guidelines 2022: what is new?. Int J Tuberc Lung Dis. 2022, 26:590-1. 10.5588\/ijtld.22.0263","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.03.013","article-title":"Update of drug-resistant tuberculosis treatment guidelines: a turning point","volume":"130 Suppl 1","author":"Vanino E","year":"2023","unstructured":"Vanino E, Granozzi B, Akkerman OW, et al.. Update of drug-resistant tuberculosis treatment guidelines: a turning point. Int J Infect Dis. 2023, 130 Suppl 1:S12-5. 10.1016\/j.ijid.2023.03.013","journal-title":"Int J Infect Dis"},{"key":"ref44","unstructured":"World health organization. Global tuberculosis report. (2021). Accessed. June 20, 2023: https:\/\/www.who.int\/publications\/digital\/global-tuberculosis-report-2021."},{"key":"ref45","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: Treatment - drug-resistant tuberculosis treatment. (2022). Accessed: June 20, 2023: https:\/\/www.who.int\/publications\/i\/item\/9789240063129."},{"key":"ref46","unstructured":"New treatment for TB. (2024). Accessed. May 16, 2024: http:\/\/ttps:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023\/featured-top...."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa BT","year":"2022","unstructured":"Nyang'wa BT, Berry C, Kazounis E, et al.. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med. 2022, 387:2331-43. 10.1056\/NEJMoa2117166","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie F","year":"2022","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, et al.. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022, 387:810-23. 10.1056\/NEJMoa2119430","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/244129-treatment-and-toxicity-considerations-in-tuberculosis-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T13:32:11Z","timestamp":1718803931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/244129-treatment-and-toxicity-considerations-in-tuberculosis-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.62698","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,19]]}}}